Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in COVID-19 patients at risk for respiratory failure
NCT04393038Phase 3Terminated
- Sponsor
- Abivax
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ABX464 with Placebo (2 arms). Primary endpoint: Rate of Responders: Patients Who Do Not Require High-flow Oxygen, Invasive or Non-invasive Mechanical Ventilation Within 28 Days and Who Are Alive. Started Jul 2020; status: terminated.
02
Drugs
obefazimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04393038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393038.